<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452189</url>
  </required_header>
  <id_info>
    <org_study_id>17-00963</org_study_id>
    <nct_id>NCT03452189</nct_id>
  </id_info>
  <brief_title>The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome</brief_title>
  <official_title>The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if multiple doses of vancomycin over the course of&#xD;
      3 months will perturb the intestinal flora (microbiome) and result in reduced serum&#xD;
      concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the&#xD;
      study will permit investigators to assess the variability of serum uremic retention solute&#xD;
      concentrations with and without antibiotic over a three-month period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Actual">August 18, 2018</completion_date>
  <primary_completion_date type="Actual">August 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized double-blinded placebo-controlled crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Concentration Measure of Indoxyl Sulphate (IS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Plasma concentrations of IS were measured by HPLC (high pressure liquid chromatography).&#xD;
Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Plasma Concentration Measure P-Cresyl Sulphate (PCS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Plasma concentrations of P-Cresyl Sulphate (PCS) were measured by HPLC (high pressure liquid chromatography)&#xD;
Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>250mg of oral vancomycin First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After 3 months, initial experimental group will be switched to placebo for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After three months, the control group will be crossed over to weekly oral vancomycin (250mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Oral vancomycin 250mg capsules</description>
    <arm_group_label>250mg of oral vancomycin First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
    <other_name>vancomycin hydrochloride capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Pills distributed by Research Pharmacy labeled &quot;placebo.&quot;</description>
    <arm_group_label>250mg of oral vancomycin First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stable chronic kidney disease on hemodialysis with a fistula or an AV&#xD;
             graft.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Antibiotics received within the last 3 months;&#xD;
&#xD;
          -  recent diarrhea&#xD;
&#xD;
          -  known allergy to vancomycin&#xD;
&#xD;
          -  history of C. difficile infection&#xD;
&#xD;
          -  elevation of white blood cell count or fever within one week of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome Lowenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <results_first_submitted>October 22, 2020</results_first_submitted>
  <results_first_submitted_qc>March 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2021</results_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03452189/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>250mg of Oral Vancomycin First, Then Placebo</title>
          <description>250mg of Oral Vancomycin given for 3 months then crossed over to placebo for additional 3 months (no washout period).</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then 250mg of Oral Vancomycin</title>
          <description>Placebo given for 3 months then crossed over to 250 mg of Oral Vancomycin for additional 3 months (no washout period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (3 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>insufficient samples of plasma and stool</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intervention 2 (3 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo First or 250mg of Oral Vancomycin First (Crossover After 3 Months)</title>
          <description>Total cohort</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other or more than one</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Concentration Measure of Indoxyl Sulphate (IS)</title>
        <description>Plasma concentrations of IS were measured by HPLC (high pressure liquid chromatography).&#xD;
Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported</description>
        <time_frame>4 weeks</time_frame>
        <population>As there was no &quot;washout period&quot; following vancomycin, for the analysis of vancomycin effect, investigators compared the changes in solute levels in all 10 subjects while receiving vancomycin to the changes seen in the 5 &quot;Z&quot; series subjects while receiving placebo as the initial treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>250mg of Oral Vancomycin First, Then Placebo</title>
            <description>250mg of Oral Vancomycin given for 3 months then crossed over to placebo for additional 3 months (no washout period).</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 250mg of Oral Vancomycin</title>
            <description>Placebo given for 3 months then crossed over to 250 mg of Oral Vancomycin for additional 3 months (no washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Concentration Measure of Indoxyl Sulphate (IS)</title>
          <description>Plasma concentrations of IS were measured by HPLC (high pressure liquid chromatography).&#xD;
Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported</description>
          <population>As there was no &quot;washout period&quot; following vancomycin, for the analysis of vancomycin effect, investigators compared the changes in solute levels in all 10 subjects while receiving vancomycin to the changes seen in the 5 &quot;Z&quot; series subjects while receiving placebo as the initial treatment.</population>
          <units>µM/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.31" spread="36.3"/>
                    <measurement group_id="O2" value="9.71" spread="49.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Concentration Measure P-Cresyl Sulphate (PCS)</title>
        <description>Plasma concentrations of P-Cresyl Sulphate (PCS) were measured by HPLC (high pressure liquid chromatography)&#xD;
Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported</description>
        <time_frame>4 weeks</time_frame>
        <population>As there was no &quot;washout period&quot; following vancomycin, for the analysis of vancomycin effect, investigators compared the changes in solute levels in all 10 subjects while receiving vancomycin to the changes seen in the 5 &quot;Z&quot; series subjects while receiving placebo as the initial treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>250mg of Oral Vancomycin First, Then Placebo</title>
            <description>250mg of Oral Vancomycin given for 3 months then crossed over to placebo for additional 3 months (no washout period).</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then 250mg of Oral Vancomycin</title>
            <description>Placebo given for 3 months then crossed over to 250 mg of Oral Vancomycin for additional 3 months (no washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Concentration Measure P-Cresyl Sulphate (PCS)</title>
          <description>Plasma concentrations of P-Cresyl Sulphate (PCS) were measured by HPLC (high pressure liquid chromatography)&#xD;
Assessed weekly between day 0 and Week 4; change from baseline/day 0 to Week 4 reported</description>
          <population>As there was no &quot;washout period&quot; following vancomycin, for the analysis of vancomycin effect, investigators compared the changes in solute levels in all 10 subjects while receiving vancomycin to the changes seen in the 5 &quot;Z&quot; series subjects while receiving placebo as the initial treatment.</population>
          <units>µM/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.51" spread="127.00"/>
                    <measurement group_id="O2" value="0.64" spread="79.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>250mg of Oral Vancomycin First</title>
          <description>After 3 months, initial experimental group will be switched to placebo for 3 months.&#xD;
Vancomycin: Oral vancomycin 250mg capsules&#xD;
Placebo: Placebo Pills distributed by Research Pharmacy labeled &quot;placebo.&quot;</description>
        </group>
        <group group_id="E2">
          <title>Placebo First</title>
          <description>After three months, the control group will be crossed over to weekly oral vancomycin (250mg)&#xD;
Vancomycin: Oral vancomycin 250mg capsules&#xD;
Placebo: Placebo Pills distributed by Research Pharmacy labeled &quot;placebo.&quot;</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jerome Lowenstein</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>+1 212 263 5635</phone>
      <email>Jerome.Lowenstein@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

